{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-24-000046","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.818837+00:00","generated_at":"2026-06-01T07:12:28.054410+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allogene restructures JV; ownership diluted to 15.4%, license royalty amended to flat mid-single-digit","bullets":["JV acquires Overland US (lead asset OL-101, autologous GPRC5D-BCMA CAR-T for multiple myeloma).","Overland's ownership in JV increases to 69.63%; Allogene's drops to 15.37% after share incentive plan increase.","Exclusive license royalty changed to flat mid single-digit on net sales in territory, no longer subject to reductions.","Allogene gains termination rights for funding default or failure to initiate tech transfer; license auto-terminates if Allogene's ownership <7.5% unless mutual plan agreed.","Overland distributes all JV shares to HH BioPharma Holdings (HBP), which gets 3 of 5 board seats."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-24-000046","json":"https://secwatch.observer/filing/0001737287-24-000046.json","markdown":"https://secwatch.observer/filing/0001737287-24-000046.md","text":"https://secwatch.observer/filing/0001737287-24-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000046/0001737287-24-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000046/allo-20240524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:12:28.054410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}